Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01997333
Title Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

triple-receptor negative breast cancer

Therapies

Glembatumumab vedotin

Capecitabine

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.